AbbVie (ABBV)

Total return at 5 years: 3.7%/year = 0.7% appreciation + 3.0% dividend. The target price ($291) is ex-dividend; the $43 in dividends collected over 5 years are added separately.

The methods disagree: one places the value today above the price ($281) and the other below.

Today — expensive, no margin of safety: at $281 trades ~3.9% above its value discounted to today (~$271); the expected return does not even reach the risk-free rate (4.5%).

At 5 years — Preserva valor: the target price ($291) plus dividends yield just enough to preserve nominal capital, below the required 4% floor.

The bridge: the return at 5 years falls below the risk-free rate (4.5%) — which is why there is not even a discount to today's value. To require a 15% annual return, it would need to be bought at ~$173.

Educational / informational. Does not constitute investment advice.

The inverse approach: instead of projecting growth to obtain the value, the market price ($281) is taken as given and it solves for what annual owner-earnings growth would need to hold for 5 years for the present value —at the method's rate (4.5%, no-growth terminal)— to equal that price. It is the disconfirmation test: the expectations the price already pays for, contrasted against the method's projection.

The market discounts less growth (-0.1%/year) than we project (7.0%/year) → if the base case holds, there is margin: perception is more pessimistic than the estimated reality.

That growth implies ~$22.4 bn of owner earnings in year 5 (vs ~$31.6 bn of our base case). It recalculates if the DCF assumptions are edited.

Year-by-year projection of the selected scenario. From each year, two versions of the flow are derived: growth FCF (operating flow − total capex, the cash surplus) and maintenance FCF (the owner earnings: what the business yields if it only sustains its capacity). The flow is returned almost in full (dividend + buyback) or redeployed into the operation, so that EV stays roughly flat and multiples compress because the metric grows, not because of cash accumulation. The valuation is done on NOPAT (EV/NOPAT). In edit mode, revenue, margins, capex, and exit multiples can be adjusted.

Rolling grid: year 0 is the real TTM (revenue $64.4bn to Jun-2026, XBRL). ABBV is a quality pharmaceutical company that has come through the post-Humira transition: Skyrizi + Rinvoq ($28.9bn in the TTM, +31%) are already several times Humira (−36% in the quarter) and have more than replaced it. It is valued at the enterprise level, on a normalized adjusted base (~$22.5bn, EPS ~$12.7, ≈ the real TTM FCF of ~$18bn): GAAP ($2.36 of EPS) is pure noise —~$7.4bn/year of Allergan intangible amortization embedded in cost— and reported adjusted FY25 ($10.00) was depressed by a peak of pipeline spending (IPR&D $2.76/share; the company's guidance for fiscal 2026 is $13.87-14.07 per share). Earnings compound ~7%/year (Skyrizi/Rinvoq + aesthetics/oncology) toward ~$32.3bn (EPS ~$18.2). Exit multiple 16× adjusted after-tax operating income (base; adverse 14× / favorable 18×), disciplined by the Skyrizi expiry (2033). The multiple goes on after-tax operating income, which is pre-interest, so net debt of ~$63bn is subtracted once, in the bridge. The present-value lens keeps its own convention: its flow is adjusted earnings, already post-interest, and that is why it does not subtract the debt. With the thesis already de-risked, the return is made up of modest appreciation + the dividend (growing). No share path: buybacks are modest (≈ SBC).

Today's elevated multiple is the price of growth: if the business grows, the entry point cheapens on its own going forward (the metric grows while EV stays roughly flat). The exit multiple at 3 years is higher than the terminal at 5 years —at 3 years there is more growth still ahead—, so the value curve shows whether value creation is concentrated in the early or the later years. The required return is applied to the base scenario.

They are valued separately, with their own rationale, and are not incorporated into the base or the verdict (they are excess return). When assigning them value — in Editmode —, the total with optionalities updates live, without moving the base.

The verdict, the base CAGR, and the margin of safety are always calculated on the base; optionalities do not alter them (with optionalities at $0 they do not move).

Each card fixes a required annual return and answers: if the business is worth $291 in 5 years, what is the maximum that can be paid today to obtain that return? Since it now trades at $281, the margin of safety is how much cheaper the market is than that maximum. The three thresholds: 4% covers inflation (the floor), 10% is the long-term average return, and 15% is the level of a great investment.

With a target price of $291 in 5 years plus $43 of dividends collected (the dividend adds to the return, not to the price) and a required return of 4.5% annually, the maximum to pay today is $271. Against the current market price ($281), the margin of safety is -3.9% (trades above the maximum → a premium is paid) and the total return at that price would be 3.7% annually.

• EV/NOPAT on the normalized adjusted result. Valued at the enterprise level on EV/NOPAT over normalized adjusted after-tax operating income (GAAP is noise; FY25 adjusted was depressed by IPR&D). Total debt ~$65bn (net debt ~$63bn from the acquisitions) is subtracted in the bridge.
• The transition already priced in. With the successor thesis already de-risked, it trades at an EV/NOPAT of 21×. The transition bargain has already been captured.
• Price versus quality. At an EV/NOPAT of 21×, the price already recognizes the quality and growth of the successors: not a clean bargain.
• The DCF at the risk-free rate. The DCF (second lens, on normalized adjusted earnings) converges close to the price: at this multiple on quality earnings, the margin is moderate.
• Margin of safety at the end. At ~$281 the base return (~+4%) comes from ~7% growth + the dividend (2.5%); the multiple is disciplined toward ~16× on the 2033 patent expiration. Moderate margin — quality at a full price.
• Growing dividend. Yield 2.5%, growing (+204% over 10 years), a dividend aristocrat counting the Abbott legacy — a strong return anchor, covered by real FCF (~$17.8bn, ~1.5× the dividend).

• ✓ ROIC exceeds the cost of capital (~10%)
• ✓ High incremental ROIC (compounding)
• ✓ CFROIC backs up the ROIC (99%, cash vs. accruals)
• ✓ Healthy balance sheet (low corporate debt)
• ✓ Durable competitive moat (multiple advantages)

• Strong, predictable cash flow. FCF ~$17.8bn/year (operating cash flow $19.0bn minus ~$1.2bn of capex), real and substantial; conversion of ~4× GAAP earnings (~$4.2bn) — non-cash amortization and the contingent consideration charge are the difference. The cash generation of a large-scale pharmaceutical.
• Return on capital. High ROIC (~22%), well above the 10% bar, though diluted by Allergan goodwill ($36bn). Returns on Skyrizi/Rinvoq (organic) are astronomical.
• GAAP is misleading. GAAP EPS ($2.36) suggests a P/E of more than 100×, absurd: ~$7.4bn/year of Allergan amortization and the contingent consideration charge (up to $6.5bn/year) depress it without costing cash that same year. It is valued on the adjusted result (or FCF).
• Lumpy IPR&D. Adjusted earnings include acquired in-process R&D expense (IPR&D), which is lumpy: FY2025 had a spike ($2.76/share) that depressed the adjusted figure to $10 — it is normalized for valuation.
• SBC immaterial. Stock-based compensation (~$989M, ~1.5% of revenue, ~5.6% of real FCF) is immaterial → no SBC trap; the adjusted metric and owner-FCF converge.
• Contingent consideration. A large non-cash charge (fair value of contingent consideration, $6.5bn in 2025 on a liability that is already $25.4bn, up from $21.7bn in 2024) inflates GAAP costs — a paradox: better Skyrizi sales raise the charge — the adjusted figure excludes it, but the cash payments are real and growing ($2.865bn in 2025, vs $1.622bn in 2023) — a cash drag that does need watching.

Annual levels from the official filing (10-K); the % over each bar is the year-over-year (YoY) growth vs the prior year.

AbbVie earns money with high-margin patented drugs; the key is the replacement cadence: Skyrizi + Rinvoq (immunology, +40-50%) more than offset Humira's decline (−49% from biosimilars), though they already make up ~42% of total net revenue. Operating cash flow is clean and substantial (operating cash flow $19.0bn, real FCF ~$17.8bn after ~$1.2bn of maintenance capex); GAAP earnings are distorted by Allergan intangible amortization (~$7.4bn non-cash) and by the growing contingent consideration charge (up to $6.5bn non-cash, tied to Skyrizi's success) — normalized adjusted earnings are used instead (FY25 adjusted was depressed by a spike in pipeline spend, IPR&D).

The % are the annual (year-over-year) growth: each year —historical and projected— vs the prior one; the TTM (trailing 12m) vs the TTM of a year ago, to avoid overlapping windows. The historicals are exact figures from the official filings; the projected years come from the year-by-year model (the intermediate years without their own series are interpolated between the anchors). The projected columns (+1y…+5y) are 12-month windows counted from the TTM close (30-jun-2026): the projection starts from the most recently reported data, not the fiscal year. The projected base is realistic and unbiased — the risk discount is applied at the end, via the required return. The rationale for each metric is in the (i).

• Real growth, not nominal. The +8.6% revenue growth is real (Skyrizi/Rinvoq volume); accelerating to +12% in Q1'26. Adjusted earnings growth is real (mix + scale), not inflationary.
• Where the engine comes from. Immunology (Skyrizi +50%, Rinvoq +39%) is the engine, offsetting the drop in Humira; neuroscience (Vraylar, Vyalev) at a double-digit rate. Oncology and aesthetics are flatter.
• Humira transition overcome. The company's biggest test: the successors (Skyrizi + Rinvoq = 5.7× Humira), with Rinvoq demonstrating clinical superiority over AbbVie's own Humira in the SELECT-SWITCH study (oct-2025), more than replaced the top-selling drug and re-accelerated revenue — the best replacement case in the industry.
• Realistic growth. The base case projects adjusted earnings growing ~7%/year (from ~$22.5bn toward ~$32.3bn), as Skyrizi/Rinvoq mature and the pipeline contributes — decelerating toward the 2033 patent expiration.
• Reinvestment runway. Ample: ~$9.1bn of research + pipeline M&A (~90 compounds, Capstan/Gilgamesh/Gubra in obesity/ADARx in 2025); the test is the ROIC of the acquisitions against the goodwill (mixed: ImmunoGen good, Cerevel bad).
• Concentration + patent expiration. Skyrizi + Rinvoq already make up ~42% of 2025 total net revenue (each individually >10%), with the composition patent expiring in 2033 for both (Rinvoq could extend to 2037, conditional on pediatric exclusivity, not yet confirmed); the market will start discounting the next cliff toward the end of the decade.

• Relevant in 10 years / recurrence. Yes — chronic treatments in immunology, neuroscience, and oncology are structural, recurring demand; health-care spending grows with demographics. Each individual drug expires with its patent.
• Differentiated product. Yes while the patent lasts (a high-margin monopoly); once it expires, the biosimilar commoditizes it (Humira −49%). The durable moat is the replacing pipeline, not a product.
• Share / position. Global leader in immunology (the largest area in pharma) with Skyrizi/Rinvoq; US aesthetics leader with Botox, with indication expansion in China (2025). Dominant positions in its niches.
• Pricing power. High while the patent lasts, but Medicare price reform (Imbruvica 2026, Vraylar 2027, Botox 2028) increasingly erodes it in mature drugs; gross list price is already heavily discounted (rebates/chargebacks $65.1bn in 2025, more than net revenue).
• Operating leverage. Very high incremental margin (the cost of an additional dose is low); adjusted operating margin ~50%. Research scale is the fixed cost to leverage.
• Recession behavior. Defensive: chronic treatments are not discretionary (aesthetics is, in part). The risk is not the economic cycle but patent expiries, price reform, and the pipeline.

Not all debt is equal: only the structural needs refinancing; the rest is operational (self-liquidating).

Structural debt is what is exposed to the contraction phase of the cycle; operational debt (leases, matched funding) self-liquidates with the business.

• ✓Leverage (net debt / EBITDA)Net cash $0 bn
• ✓Interest coverage (EBIT / interest)10.3x
• –Liquidity (current ratio)no data
• ✓Cash quality (CFROIC vs ROIC)CFROIC backs 99% of ROIC
• ✓Value creation (ROIC − 10% bar)+12pp
• ✓Malinvestment test (capex vs incremental ROIC)Productive investment (1.6x)
• !Float / working capitalConsumes cash $0.5 bn (positive WC)
• ✓Dilution (SBC % of revenue + shares)SBC 1.5% of revenue

A traffic-light interpreted by the method (not generic): float (negative WC) adds up, capex is judged by incremental ROIC (malinvestment test), and a lender is not subjected to corporate solvency. The (i) shows the derivation of each number.

• Negative book equity (artifact). Equity is negative (−$6.7bn), but it is an accumulated GAAP artifact — intangible amortization and the growing contingent consideration charge ($25.4bn, tied to Skyrizi's success) exceed accounting earnings — not a distress signal. Moody's raised the rating to A2 in feb-2026 looking at cash flow, not the book.
• Leverage from acquisitions. Total debt ~$65bn including finance leases (net debt ~$63bn, from Allergan/ImmunoGen/Cerevel, ~3× EBITDA), with $8.65bn of maturities concentrated in 2029 — high for a pharmaceutical, but covered by real FCF (~$17.8bn); ABBV is deleveraging (Moody's raised the rating to A2 in feb-2026). The risk is leverage, not solvency.
• Cash generation. Operating cash flow $19.0bn, minimal capex (~$1.2bn, asset-light) → real FCF ~$17.8bn; comfortably covers the dividend (~$12bn, ~67% of real FCF) and funds M&A + deleveraging. A substantial cash machine.
• Dividend coverage. The dividend (~$12bn) consumes ~67% of real FCF (~$17.8bn) — well covered by cash, though >100% of depressed GAAP earnings (which is why book equity falls, along with the contingent consideration charge). Cash, not the book, is what matters.
• Litigation (Allergan). Litigation inherited from Allergan (opioids ~335 pending suits; Biocell breast implants ~3,165 combined ALCL and other claims, with the Amsterdam court dismissing the Dutch claims in dec-2025, appealable) plus new fronts: the Sheet Metal Workers Health Plan antitrust suit (jan-2025, pending) over Humira rebates, and patent litigation AbbVie initiated against generic makers of Ubrelvy and Qulipta. Accrued reserve $1.6bn (down from $2.5bn); a $572M tax dispute was resolved in AbbVie's favor in feb-2026. Not individually material per the company, but worth watching.

Who owns the shares — the alignment and whether there is a controlling shareholder.

• Capital allocation. Priority dividend (growing, ~67% of real FCF) + pipeline M&A + deleveraging; buybacks are low and dropped sharply (~$606M in 2025 vs ~$1.3bn in 2024). Disciplined on the goal (dividend + investment grade, reinforced by Moody's upgrade to A2 in feb-2026); the test is the ROIC of the acquisitions.
• Alignment / skin in the game. Professional management (insiders <1%, no founder); Michael has a 6× salary ownership guideline. Alignment through performance-tied compensation, not founder ownership.
• Pipeline M&A. Serial acquirer (ImmunoGen, Cerevel, Capstan, Gilgamesh, Ichnos Glenmark, Gubra, ADARx): the test is the ROIC — mixed (Elahere/ImmunoGen good, emraclidine/Cerevel a $4.5bn impairment failure). The M&A machine is central to the thesis.
• Succession / continuity. Michael (a 30+ year veteran) succeeded Gonzalez in an orderly transition — elected board chair in feb-2025, effective jul-2025, when Gonzalez retired from the board — providing continuity of strategy and deep knowledge. The team executed the Humira transition exceptionally well.

• GAAP is brutally misleading: GAAP EPS ($2.36) makes the P/E look like more than 100×, absurd — Allergan intangible amortization (~$7.4bn/year, non-cash) depresses GAAP without costing cash (along with the contingent consideration charge, up to $6.5bn/year). On adjusted results (or real FCF of ~$17.8bn) the multiple is in the low double digits, not more than 100×.
• The Humira fear has already dissipated: the market feared the loss of the top-selling drug would sink ABBV; Skyrizi + Rinvoq not only replaced it but re-accelerated revenue — the perception-reality gap has already closed.
• The negative book equity (−$6.7bn) alarms the unwary eye, but it is an accumulated GAAP artifact: intangible amortization (~$7.4bn/year) and the charge from the fair-value increase in contingent consideration (~$3.8-6.5bn/year in 2023-2025, tied to Skyrizi's own success) exceed accounting earnings without being a cash event of the same size; Moody's raised the rating to A2 in feb-2026 looking at real cash flow (~$17.8bn), not the book.

The large perception-reality gap (the Humira fear, the misleading GAAP, the negative equity) has already resolved as the successors proved the thesis out. What remains is a quality pharmaceutical at a full price (EV/NOPAT 21×) — not a bargain, but recognized quality with real growth ahead.

The annual return (CAGR at 5 years) in each scenario, with the total period return below — the margin of safety made visual: upside range wide, downside range narrow.

Even in the bear scenario, the return holds at -3%/year (-15% total): the margin of safety protects the downside. The bull (+8%/year, +49% total) exceeds it comfortably — a favorable asymmetry, with a narrow downside range and a wide upside range.

• Skyrizi/Rinvoq patent expiration (2033, extension to 2037 conditional). Growth is concentrated in two drugs that already make up ~42% of 2025 total net revenue (each individually >10%), flagged by the company as the #1 risk in its Item 1A; the pipeline must build the next generation before 2033 — Rinvoq's extension to 2037 depends on pediatric exclusivity being confirmed, which has not yet been granted.
• Medicare price reform + rebate litigation. Price setting already affects Imbruvica (2026), Vraylar (2027), and Botox (2028); a new antitrust suit (Sheet Metal Workers Health Plan, jan-2025, pending) adds to it, questioning whether Humira's rebate practices slowed biosimilars — two fronts of pressure on price and commercial strategy.
• Pipeline / M&A that doesn't pay off, and active patent litigation. After the emraclidine failure (Cerevel, $4.5bn impairment), the risk is that the acquisitions won't build the next wave; and AbbVie is already defending Ubrelvy (since mar-2024) and Qulipta (since dec-2025/jan-2026) with its own litigation against generic makers — pressure on the neuroscience franchise has arrived earlier than the 2033 horizon suggests.
• ~$65bn of debt + growing contingent consideration. Total debt (including finance leases) is $65.0bn, with $8.65bn of maturities concentrated in 2029; added to this is a contingent consideration liability (classified as Level 3 fair value) that has already reached $25.4bn and keeps growing with Skyrizi's success, with $2.865bn of cash payments in 2025. Moody's raised the rating to A2 in feb-2026, looking at cash flow.
• Valuation premium. At an EV/NOPAT of 21× the margin is moderate; if growth disappoints or the market starts discounting the 2033 expiration, the multiple compresses.

Each thinker's analytical framework applied to our data.

• Buffett / Graham Quality + margin of safety

  A wide moat and ROIC 22% above the 10% bar, but the price sits above value (no margin) → great business, expensive.

• Peter Lynch Growth at a reasonable price (GARP)

  A stalwart growing 7% at a multiple/growth of 3.1 → expensive for its growth.

• Joel Greenblatt Cheap and high-return (Magic Formula)

  Earnings yield 6% (EBIT/EV) + ROIC 22% → brushes the Magic Formula.

• Howard Marks Perception vs reality + cycle

  The price discounts -0% vs our 7%: perception is more pessimistic than reality, with an identified source of the discount.

• Seth Klarman Capital protection (bear scenario)

  Bear-scenario floor -7%/yr, bull-scenario ceiling +6%/yr over 5y: reasonable asymmetry, without an ample cushion.

• Pat Dorsey Moat strength (Five Rules)

  A wide moat, stable; sources: intangibles, efficient scale, switching costs, cost advantage → passes the Five Rules.

• Aswath Damodaran Expectations implied by the price

  Justifying the price requires discounting -0%, within what we project (7%) — the story squares with the numbers.